PERK Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-12194
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
Dot Blot, ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Synthetic peptide taken within amino acid region 1000-1050 on human Eukaryotic translation initiation factor 2-alpha kinase 3 protein.
Clonality
Polyclonal
Host
Rabbit
Scientific Data Images for PERK Antibody
Immunohistochemistry-Paraffin: PERK Antibody [NBP3-12194]
Immunohistochemistry-Paraffin: PERK Antibody [NBP3-12194] - 1:100 dilution in IHC Blocking buffer. DAB (brown) staining and Hematoxylin QS (blue) counterstain. 40X magnification. FFPE.Applications for PERK Antibody
Application
Recommended Usage
Dot Blot
1:4000
ELISA
1:4000
Immunohistochemistry
1:50-1:100
Immunoprecipitation
1:150
Western Blot
1:500
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
Contains Tris, HCl/glycine buffer (pH 7.4-7.8), 30% glycerol, 0.5% BSA, along with cryo-protective agents, and HEPES (exact storage and stabilization buffer information is proprietary).
Preservative
0.02% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Store at -20C long term. Avoid freeze-thaw cycles.
Background: PERK
Long Name
Eukaryotic Translation Initiation Factor 4B
Alternate Names
EIF2AK3, PEK, WRS
Gene Symbol
EIF2AK3
Additional PERK Products
Product Specific Notices for PERK Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...